MENU
IDNA
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

IDNA stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM... Show more

Category: #Health
IDNA
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IDNA with price predictions
Sep 25, 2026

Aroon Indicator for IDNA shows an upward move is likely

IDNA's Aroon Indicator triggered a bullish signal on September 03, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 198 similar instances where the Aroon Indicator showed a similar pattern. In 176 of the 198 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on IDNA as a result. In 75 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for IDNA just turned positive on September 22, 2026. Looking at past instances where IDNA's MACD turned positive, the stock continued to rise in 45 of 51 cases over the following month. The odds of a continued upward trend are 88%.

Following a +2.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in 239 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for IDNA moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 20 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

IDNA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares Genomics Immunology and Healthcare ETF (IDNA) ETF is 32.31B. The market cap for tickers in the group ranges from 345.89M to 367.07B. MRK holds the highest valuation in this group at 367.07B. The lowest valued company is OCGN at 345.89M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Genomics Immunology and Healthcare ETF (IDNA) ETF was 5%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was 50%. DNA experienced the highest price growth at 35%, while KURA experienced the biggest fall at -8%.

Volume

The average weekly volume growth across all stocks in the iShares Genomics Immunology and Healthcare ETF (IDNA) ETF was -59%. For the same stocks of the ETF, the average monthly volume growth was -6% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 67
Price Growth Rating: 45
SMR Rating: 84
Profit Risk Rating: 81
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
IDNA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com